TC-1698

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TC-1698
TC-1698 structure.png
Systematic (IUPAC) name
2-pyridin-3-yl-1-azabicyclo[3.2.2]nonane
Clinical data
Legal status Legal
Identifiers
ATC code ?
PubChem CID 10130417
Chemical data
Formula C13H18N2 
Mol. mass 202.295
 YesY (what is this?)  (verify)

TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.[1] It has neuroprotective effects in animal studies,[2] and has been used as a lead compound to find further potent derivatives.[3]

References[edit]

  1. ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.  edit
  2. ^ Marrero, M.; Papke, R.; Bhatti, B.; Shaw, S.; Bencherif, M. (2004). "The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo3.2.2nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase". The Journal of Pharmacology and Experimental Therapeutics 309 (1): 16–27. doi:10.1124/jpet.103.061655. PMID 14722323.  edit
  3. ^ Bhatti, B.; Strachan, J.; Breining, S.; Miller, C.; Tahiri, P.; Crooks, P.; Deo, N.; Day, C.; Caldwell, W. (2008). "Synthesis of 2-(pyridin-3-yl)-1-azabicyclo3.2.2nonane, 2-(pyridin-3-yl)-1-azabicyclo2.2.2octane, and 2-(pyridin-3-yl)-1-azabicyclo3.2.1octane, a class of potent nicotinic acetylcholine receptor-ligands". The Journal of Organic Chemistry 73 (9): 3497–3507. doi:10.1021/jo800028q. PMID 18363376.  edit